Venus MedTech FY26 H1 net loss widens 41.9% to RMB 191.31 million; revenue falls 27.6% to RMB 135.5 million

• Venus Medtech posted revenue of RMB 135.5 million, down 27.6% year over year, for the six months ended June 30, 2026.
• Loss attributable to owners widened to RMB 191.31 million; basic and diluted loss per share deepened to RMB 0.44.
• Gross profit fell 32.2% to RMB 93.52 million; gross margin slid to 69% from 73.7%.
• Overseas revenue rose 24.6% to RMB 50.73 million, lifting its share of total revenue to 37.4%; overseas valve sales topped 530 units.
• Management cited domestic TAVR pricing-system restructuring and slower aortic stenosis procedure growth; VenusP-Valve expanded to Israel, Peru, Vietnam.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309520), on August 31, 2026, and is solely responsible for the information contained therein.